Merck: to present new data at ACC.25

(CercleFinance.com) - Merck announced that new clinical research data will be presented at the American College of Cardiology's Annual Scientific Session and Exposition (ACC.
25) of the American College of Cardiology in Chicago from 29 to 31 March.

The data will aim to highlight innovative advances for people with cardiovascular disease

Data from the phase 3 ZENITH trial evaluating WINREVAIR TM when combined with background therapy in adults with high-risk mortality WHO functional class (FC) III or IV pulmonary arterial hypertension (PAH, group 1) will be presented.

Four outcomes research presentations focusing on Merck's cholesterol management will also be presented during the meeting.

We are particularly excited to share research from the Phase 3 ZENITH trial evaluating WINREVAIR in the treatment of PAH as a late-breaking presentation, it said.


Copyright (c) 2025 CercleFinance.com. All rights reserved.